Acute Respiratory Distress Syndrome (ARDS) Market Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis by DelveInsight

DelveInsight has launched a new report on “Acute Respiratory Distress Syndrome (ARDS) - Market Insights, Epidemiology & Market Forecast–2030”.

Some facts of the report:

1.       Total incident population of ARDS in the 7MM observed to be 815,490 in 2017 for the study period 2017– 2030.

2.       DelveInsight’s estimates show higher incidence of ARDS in the United States with an estimated number of 497,947 cases in 2017

3.       Among the EU-5 countries, Germany had the highest incident population of ARDS with 148,302 cases.

4.       Among the EU-5 countries, Spain had the lowest incident population of 20,839 in 2017.

Request for Sample Page: https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-ards-market

Key Benefits of the Report:

1.       Acute Respiratory Distress Syndrome Market report covers a descriptive overview and comprehensive insight of the Acute Respiratory Distress Syndrome epidemiology and Acute Respiratory Distress Syndrome market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)

2.       Acute Respiratory Distress Syndrome market report provides insights on the current and emerging therapies.

3.       Acute Respiratory Distress Syndrome market report provides a global historical and forecasted market covering drug outreach in 7 MM.

4.       Acute Respiratory Distress Syndrome market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Acute Respiratory Distress Syndrome market.

Request for Sample Page: https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-ards-market

Acute respiratory distress syndrome (ARDS) is a rapidly progressive disease occurring in critically ill patients. The main complication in ARDS is that fluid leaks into the lungs making breathing difficult or impossible.

The causes of ARDS are divided into two categories: direct or indirect injuries to the lung. Some of the direct injuries to the lung include pneumonia, aspiration, trauma, and others. Whereas the indirect injuries to the lung include inflammation of the pancreas, severe infection (also known as sepsis), blood transfusions, burns, and medication reactions.

The few symptoms of ARDS are, shortness of breath, cough, and fever. In some cases, those with ARDS also have fast heart rates and rapid breathing. Occasionally, patients of ARDS experience chest pain, especially during inhalation. Some patients also experience bluish coloring of nails and lips due to the severely decreased oxygen levels in the blood. There are several risk-factors that may escalate the risk for ARDS. This involves obesity, alcohol abuse, chemotherapy, low-protein in blood.

“The highest number of incident cases were assessed for ARDS due to pneumonia, in all the 7MM countries, except the United Kingdom, in which Sepsis was the primary risk factor for ARDS”

Request for Sample Page: https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-ards-market

The launch of the emerging therapies is expected to significantly impact Postherpetic Neuralgia treatment scenario in the upcoming years:-

Drugs covered:

·         Traumakine

·         Bio-11006

·         Ulinastatin

·         MultiStem

·         Solnatide (AP301)

·         APN01 (GSK2586881)

·         GSK2862277

·         IC14

·         Remodulin (Treprostinil Inhalation Solution)

The key players in Postherpetic Neuralgia market are:

·         Faron Pharmaceuticals

·         BioMarck Pharmaceuticals

·         Techpool Bio-Pharma

·         Athersys

·         APEPTICO Forschung und Entwicklung GmbH

·         Apeiron Biologics/GlaxoSmithKline

·         GlaxoSmithKline

·         Implicit Bioscience

·         United Therapeutics

Request for Sample Page: https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-ards-market

Table of Contents:

1. Key Insights

2. Executive Summary

3. Acute Respiratory Distress Syndrome (ARDS): Market Overview at a Glance

3.1. Total Market Share (%) Distribution of ARDS in 2017

3.2. Total Market Share (%) Distribution of ARDS in 2030

4. Acute Respiratory Distress Syndrome (ARDS): Disease Background and Overview

4.1. Introduction

4.1.1. Consensus Definitions of Acute Lung Injury and Acute Respiratory Distress Syndrome (ARDS)

4.1.2. Development of Berlin Definition of ARDS

4.1.3. Problems with the AECC definition and subsequent Berlin definition of acute respiratory distress

syndrome (ARDS)

4.2. Causes and Risk Factors

4.2.1. Risk Factors of Acute Respiratory Distress Syndrome (ARDS)

4.3. Pathophysiology of Acute Respiratory Distress Syndrome (ARDS)

4.3.1. Inflammatory Processes in ARDS

4.3.2. The initial event of injury

4.3.3. Endothelial Damage

4.3.4. Specific Mediators of Inflammation and Lung Damage in ARDS

4.3.5. Altered Pulmonary Physiology in ARDS

4.3.6. Genetics

4.4. Stages of Acute Respiratory Distress Syndrome (ARDS)

4.5. Ventilator-Induced Lung Injury (VILI)

4.6. Major Determinants of VILI

4.6.1. Ventilator determinants of VILI

4.6.2. Patient determinants of VILI

4.7. Diagnosis of Acute Respiratory Distress Syndrome (ARDS)

4.7.1. Imaging techniques in ARDS

4.7.2. Imaging findings in ARDS

4.7.3. Differential Diagnosis

5. Case Reports

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. Methodology

7. 7MM Epidemiology Analysis

7.1. Total Incident Population of Acute Respiratory Distress Syndrome (ARDS) in the 7MM

7.2. Severity-specific Incident Population of Acute Respiratory Distress Syndrome (ARDS) in the 7MM

8. United States Epidemiology

8.1. Assumptions and Rationale

8.2. Total Incident Population of Acute Respiratory Distress Syndrome (ARDS) in the United States

8.3. Severity-specific Incident Population of ARDS in the United States

8.4. Incident Population of ARDS by Risk Factors in the United States

9. EU5 Epidemiology

9.1. Germany Epidemiology

9.1.1. Assumptions and Rationale

9.1.2. Total Incident Population of Acute Respiratory Distress Syndrome (ARDS) in Germany

9.1.3. Severity-specific Incidence of ARDS in Germany

9.1.4. Incident Population of ARDS by Risk Factors in Germany

9.2. France Epidemiology

9.2.1. Assumptions and Rationale

9.2.2. Total Incident Population of Acute Respiratory Distress Syndrome (ARDS) in France

9.2.3. Severity-specific Incidence of ARDS in France

9.2.4. Incident Population of ARDS by Risk Factors in France

9.3. Italy Epidemiology

9.3.1. Assumptions and Rationale

9.3.2. Total Incident Population of Acute Respiratory Distress Syndrome (ARDS) in Italy

9.3.3. Severity-specific Incidence of ARDS in Italy

9.3.4. Incident Population of ARDS by Risk Factors in Italy

9.4. Spain Epidemiology

9.4.1. Assumptions and Rationale

9.4.2. Total Incident Population of Acute Respiratory Distress Syndrome (ARDS) in Spain

9.4.3. Severity-specific Incidence of ARDS in Spain

9.4.4. Incident Population of ARDS by Risk Factors in Spain

9.5. United Kingdom Epidemiology

9.5.1. Assumptions and Rationale

9.5.2. Total Incident Population of Acute Respiratory Distress Syndrome (ARDS) in the United Kingdom

9.5.3. Severity-specific Incidence of ARDS in the United Kingdom

9.5.4. Incident Population of ARDS by Risk Factors in the United Kingdom

10. Japan Epidemiology

10.1.Assumptions and Rationale

10.2. Total Incident Population of Acute Respiratory Distress Syndrome (ARDS) in Japan

10.3. Severity-specific Incidence of ARDS in Japan

10.4. Incident Population of ARDS by Risk Factors in Japan

11. Treatment Algorithm, Current Treatment, and Medical Practices

11.1. Treatment and Support for Acute Respiratory Distress Syndrome (ARDS)

12. Proposed Guidelines for ARDS

12.1.An Official American Thoracic Society/European Society of Intensive Care Medicine/Society of Critical

Care Medicine Clinical Practice Guideline: Mechanical Ventilation in Adult Patients with Acute

Respiratory Distress Syndrome

12.2. The Clinical Practice Guideline by the Japanese Society of Respiratory Care Medicine and the Japanese

Society of Intensive Care Medicine for the management of ARDS in Japan

13. Unmet Needs

14. Off-Label Therapies for ARDS

14.1.Neuromuscular Blocking Agents (NMBAs)

14.1.1. Product Description

14.1.2. Mechanism of Action

14.1.3. Advantages and Disadvantages

14.1.4. Clinical Development

14.2. Inhaled Vasodilators

14.2.1. Product Description

14.2.2. Inhaled Pulmonary Vasodilators

14.2.3. Advantages and Disadvantages

14.2.4. Clinical Development

14.3. Corticosteroids

14.3.1. Product Description

14.3.2. Mechanism of Action

14.3.3. Advantages and Disadvantages

14.3.4. Clinical Development

15. Emerging Therapies

15.1.Key Cross Competition

15.2. Traumakine: Faron Pharmaceuticals

15.2.1. Product Description

15.2.2. Other Developmental Activities

15.2.3. Clinical Development

15.2.4. Clinical Trials Information

15.2.5. Safety and Efficacy

15.2.6. Product Profile

15.3.Bio-11006: BioMarck Pharmaceuticals

15.3.1. Product Description

15.3.2. Other Developmental Activities

15.3.3. Clinical Development

15.3.4. Clinical Trials Information

15.3.5. Product Profile

15.4.Ulinastatin: Techpool Bio-Pharma

15.4.1. Product Description

15.4.2. Other Developmental Activities

15.4.3. Clinical Development

15.4.4. Clinical Trials Information

15.4.5. Product Profile

15.5.MultiStem: Athersys

15.5.1. Product Description

15.5.2. Other Developmental Activities

15.5.3. Clinical Development

15.5.4. Clinical Trials Information

15.5.5. Safety and Efficacy

15.5.6. Product Profile

15.6. Solnatide (AP301): APEPTICO Forschung und Entwicklung GmbH

15.6.1. Product Description

15.6.2. Other Developmental Activities

15.6.3. Clinical Development

15.6.4. Clinical Trials Information

15.6.5. Safety and Efficacy

15.6.6. Product Profile

List to be continued in the report……

16. Discontinued Products

16.1.APN01 (GSK2586881): Apeiron Biologics/GlaxoSmithKline

16.1.1. Product Description

16.1.2. Other Developmental Activities

16.1.3. Clinical Development

16.1.4. Safety and Efficacy

16.1.5. Product Profile

16.2.GSK2862277: GlaxoSmithKline

16.2.1. Product Description

16.2.2. Other Developmental Activities

16.2.3. Clinical Development

16.2.4. Safety and Efficacy

16.2.5. Product Profile

16.3. IC14: Implicit Bioscience

16.3.1. Product Description

16.3.2. Other Developmental Activities

16.3.3. Clinical Development

16.3.4. Product Profile

16.4.Remodulin (Treprostinil Inhalation Solution): United Therapeutics

16.4.1. Product Description

16.4.2. Other Developmental Activities

16.4.3. Clinical Development

16.4.4. Clinical Trials Information

16.4.5. Product Profile

17. Acute Respiratory Distress Syndrome (ARDS): 7MM Analysis

17.1. Key Findings

17.2.Market Forecast Assumptions

17.3.Market Size of ARDS in the 7MM countries

17.4.Market Size of ARDS by therapies in the 7MM

18. United States: Market Outlook

19. United States Market Size

19.1.1. Total Market size of ARDS

19.1.2. Market Size of ARDS by Therapies in the US

20. EU-5 Countries: Market Outlook

20.1.Germany Market Size

20.1.1. Total Market Size of ARDS

20.1.2. Market Size of ARDS by Therapies in Germany

20.2. France Market Size

20.2.1. Total Market Size of ARDS

20.2.2. Market Size of ARDS by Therapies in France

20.3. Italy Market Size

20.3.1. Total Market Size of ARDS

20.3.2. Market Size of ARDS by Therapies in Italy

20.4. Spain Market Size

20.4.1. Total Market Size of ARDS

20.4.2. Market Size of ARDS by Therapies in Spain

20.5.United Kingdom Market Size

20.5.1. Total Market Size of ARDS

20.5.2. Market Size of ARDS by Therapies in the UK

21. Japan Market Outlook

21.1.Japan Market Size

21.1.1. Total Market Size of ARDS

21.1.2. Market Size of ARDS by Therapies in Japan

22. Market Drivers

23. Market Barriers

24. SWOT Analysis

25. KOL Views

26. Appendix

26.1.Report Methodology

27. DelveInsight Capabilities

28. Disclaimer

29. About DelveInsight